Market Outlook

By 2035, the U.S. Cancer Diagnostic Devices Market is expected to reach approximately USD 77.38 billion, expanding at a CAGR of 9.28% during the forecast period 2026–2035. The market is estimated at USD 31.86 billion in 2025, following expansion from approximately USD 23.82 billion in 2021, USD 25.41 billion in 2022, USD 27.30 billion in 2023, and USD 29.45 billion in 2024. Values in this report are expressed in USD billions.

Cancer diagnostics represents one of the most strategically important medical-device ecosystems in the United States because virtually every oncology pathway begins with detection, visualization, tissue acquisition, pathological confirmation, molecular characterization, or longitudinal imaging. More than 2.04 million new cancer diagnoses were expected in the U.S. during 2025, creating sustained procedural demand across breast imaging, CT, MRI, PET, ultrasound, endoscopy, biopsy, histopathology, molecular diagnostic instrumentation, digital pathology, and AI-assisted image interpretation.

Unlike therapeutic device markets that depend primarily on intervention volumes after a confirmed diagnosis, cancer diagnostic devices participate across screening, differential diagnosis, staging, biopsy guidance, pathology confirmation, recurrence surveillance, therapy selection, and treatment-response assessment. This gives the sector multiple revenue pools and creates recurring demand from hospital radiology departments, cancer centers, pathology laboratories, breast imaging facilities, gastrointestinal practices, pulmonary programs, urology centers, ambulatory diagnostic networks, and independent laboratories.

The U.S. market is transitioning from largely modality-specific equipment procurement toward connected diagnostic ecosystems. Health systems are increasingly evaluating whether imaging, biopsy, pathology, molecular instrumentation, and AI platforms can shorten the time from suspicious finding to confirmed diagnosis. Diagnostic technologies capable of reducing repeat procedures, improving lesion targeting, lowering nondiagnostic biopsy rates, supporting early-stage detection, and improving specialist productivity can create economic value well beyond their acquisition price.

The U.S. breast-imaging installed base illustrates the scale of diagnostic infrastructure. More than 9,000 certified mammography facilities operate nationally, supported by tens of thousands of accredited imaging units and more than 40 million reported annual mammography procedures. Similar high-volume diagnostic pathways exist across colorectal cancer screening, lung imaging, prostate imaging and biopsy, pathology, and gastrointestinal endoscopy.

Between 2026 and 2035, value growth is expected to shift increasingly toward digital breast tomosynthesis, photon-counting and spectral imaging, advanced PET technologies, robotic and navigational biopsy systems, next-generation pathology scanners, AI-assisted cancer detection, fluorescence-guided visualization, high-resolution endoscopy, multi-modal imaging, automated tissue processing, and integrated oncology diagnostic informatics.

The commercial opportunity will therefore be defined less by the sale of isolated diagnostic equipment and more by the ability of manufacturers to improve the economics and clinical reliability of the complete diagnostic journey.

 

Introduction

According to the U.S. Cancer Diagnostic Devices Market Report, the market is supported by a rare combination of high cancer incidence, broad screening infrastructure, sophisticated oncology referral networks, strong diagnostic imaging utilization, substantial pathology capacity, advanced molecular laboratories, and a regulatory environment that continues to authorize new AI-enabled and oncology-specific medical devices.

Cancer remains one of the most consequential diseases for the U.S. healthcare system. Approximately 2.04 million new cancer cases and more than 618,000 cancer deaths were projected for 2025, meaning roughly 5,600 Americans were expected to receive a cancer diagnosis every day. Breast, prostate, lung, colorectal, melanoma, hematologic, bladder, uterine, kidney, pancreatic, thyroid, and other cancers generate substantially different diagnostic workflows, creating a diversified medical-device requirement rather than dependence on any single modality.

The market includes large capital systems such as CT, MRI, PET/CT, mammography, digital pathology scanners and advanced ultrasound; procedure-driven products such as biopsy needles, forceps, breast biopsy systems, bronchoscopic biopsy technologies, navigational platforms and tissue-acquisition instruments; visualization equipment such as endoscopes and fluorescence systems; laboratory instrumentation used for oncology testing; and software-enabled devices that support lesion detection, classification, risk prediction or pathology analysis.

The U.S. diagnostic infrastructure provides substantial purchasing capacity. The hospital sector includes more than 6,000 hospitals, while large integrated delivery networks increasingly standardize imaging, pathology and procedural technologies across multiple facilities. Health-system consolidation has strengthened centralized procurement, making enterprise contracting, interoperability, service uptime, cybersecurity, software integration and lifetime operating cost increasingly important components of purchasing decisions.

Screening creates another durable layer of demand. Breast screening participation among women aged 50–74 reached approximately 80% in 2023, while cervical and colorectal screening rates remained below their full potential. Colorectal screening participation also remains particularly low among adults newly eligible in the 45–49 age group. These gaps represent both a public-health challenge and a long-term commercial opportunity for less invasive, more accessible and more workflow-efficient cancer diagnostic technologies.

From a procurement perspective, hospitals are increasingly measuring cancer diagnostic technologies against operational metrics such as scan throughput, radiologist reading time, biopsy room utilization, pathology turnaround time, diagnostic yield, repeat-procedure frequency, patient leakage, referral conversion and time to treatment. A premium diagnostic platform can therefore defend higher pricing when it increases usable capacity or reduces downstream diagnostic friction.

The market is also moving toward diagnostic convergence. Radiology, pathology, genomics and procedural visualization are gradually becoming interconnected data domains. This creates a strategic advantage for companies able to integrate hardware, software, AI algorithms, image-management platforms and clinical decision-support functionality.

 

Key Market Drivers: What’s Fueling the U.S. Cancer Diagnostic Devices Market Boom?

The primary market driver is the underlying volume of cancer. The U.S. entered 2025 with more than two million expected new cancer diagnoses, with large absolute patient pools across breast, prostate, lung and colorectal cancer. Cancer risk also increases significantly with age, creating structural demand as the U.S. population continues to age. Diagnostic-device utilization expands not only with incidence but also through follow-up scans, staging studies, pathology workups, biopsy procedures and post-treatment surveillance.

A second major driver is the economic and clinical emphasis on earlier diagnosis. Detecting cancer at a localized stage can fundamentally alter the treatment pathway for many tumor types. Health systems therefore continue to invest in mammography, low-dose CT workflows, high-resolution endoscopy, advanced ultrasound, multiparametric MRI, image-guided biopsy and pathology systems capable of identifying disease earlier and with greater diagnostic confidence.

Breast imaging remains one of the largest recurring screening-device opportunities. The U.S. mammography network performs more than 40 million procedures annually, supporting replacement cycles for digital mammography systems, digital breast tomosynthesis, breast ultrasound, biopsy guidance systems, contrast-enhanced mammography platforms and AI-assisted image interpretation.

A third driver is the expansion of image-guided and minimally invasive biopsy. Tissue diagnosis remains central to oncology, but hospitals and outpatient centers increasingly favor techniques that reduce surgical exposure while increasing diagnostic yield. Core needle biopsy, vacuum-assisted breast biopsy, transbronchial biopsy, MRI-guided biopsy, ultrasound-guided procedures, stereotactic systems, robotic bronchoscopy and navigational technologies are therefore attracting sustained investment.

The U.S. cancer biopsy opportunity is particularly attractive because diagnosis is becoming more anatomically precise. Suspicious lesions identified through advanced imaging can increasingly be targeted using image fusion, electromagnetic navigation, robotic platforms or real-time ultrasound. Reducing nondiagnostic samples has direct economic value because repeat biopsy adds cost, delays treatment and increases patient anxiety.

A fourth driver is digital pathology adoption. Traditional glass-slide pathology remains fundamental to cancer confirmation, but pathology departments are steadily moving toward whole-slide imaging, digital workflow management, remote review and algorithm-assisted interpretation. Digital pathology can help consolidate specialist expertise across hospital networks, support remote consultation, improve archive accessibility and enable AI-based quantitative analysis.

A fifth driver is AI-enabled diagnosis. The FDA has continued to authorize medical devices incorporating machine-learning functionality across radiology and pathology. Cancer applications are particularly suitable because image interpretation involves large numbers of mammograms, CT scans, MR studies, endoscopic images and histopathology slides. AI can support lesion detection, prioritization, quantification, risk prediction and decision support.

The commercial significance of AI will depend less on algorithm novelty than on workflow integration. Hospitals are increasingly skeptical of stand-alone software that generates additional alerts without clearly improving productivity. Solutions that reduce radiologist reading time, prioritize suspicious studies, increase colon-polyp detection, support prostate MRI interpretation, identify high-risk breast imaging patterns or improve pathology workflow have stronger procurement logic.

A sixth driver is diagnostic capacity expansion outside major academic hospitals. Community hospitals, ambulatory imaging networks, gastroenterology practices, urology groups, pulmonary programs and regional cancer centers are increasingly adopting technology previously concentrated in tertiary centers. This broadens the market for compact imaging systems, automated biopsy platforms, cloud-connected pathology solutions and procedure-specific diagnostic technologies.

Finally, cancer diagnostics benefits from strong innovation density. FDA oncology-device activity remains substantial, with dozens of oncology-related IVD, imaging, pathology and other medical-device authorizations occurring annually. This creates rapid technology turnover and encourages U.S. institutions to evaluate next-generation platforms earlier than many other markets.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Cancer diagnostic-device innovation is increasingly centered on four objectives: detecting disease earlier, sampling suspicious tissue more accurately, converting diagnostic information into digital data, and decreasing the time between abnormal screening and definitive diagnosis.

Advanced imaging is moving beyond basic anatomical visualization. CT platforms increasingly use improved detector technology, spectral imaging and AI reconstruction to enhance lesion characterization while managing radiation exposure. MRI systems are improving acquisition speed, diffusion imaging, multiparametric protocols and automated analysis. PET technology continues to benefit from higher detector sensitivity, improved time-of-flight performance and growing use of tumor-specific radiotracers.

Breast diagnostics is experiencing particularly strong innovation. Digital breast tomosynthesis has become embedded across much of the U.S. mammography infrastructure. Additional growth is emerging from contrast-enhanced mammography, automated breast ultrasound, AI-assisted mammographic interpretation, risk-assessment algorithms and improved stereotactic and MRI-guided biopsy systems.

Lung cancer diagnosis is another high-value innovation area. Low-dose CT screening has expanded the number of pulmonary nodules requiring clinical evaluation, creating downstream demand for advanced CT interpretation, navigational bronchoscopy, radial ultrasound, robotic bronchoscopy and peripheral lung biopsy technologies. Technologies that allow clinicians to reach smaller peripheral lesions with high diagnostic yield may gain strong adoption because early-stage lung lesions are increasingly identifiable through imaging.

Endoscopic visualization is evolving through improved optics, narrow-band and spectral imaging, computer-aided polyp detection, high-definition endoscopy, confocal imaging and AI-supported lesion characterization. Colorectal cancer prevention is especially important because endoscopy allows both identification and immediate removal of precancerous polyps.

Robotic and navigational biopsy technologies are creating a new premium device class. Systems designed to access difficult lesions in the lung, prostate or other organs can expand the addressable patient pool while improving procedural precision. For hospitals, the strategic question is whether the higher capital cost is offset by greater procedural throughput, specialist differentiation, improved biopsy yield and referral capture.

Digital pathology represents one of the most important structural changes in tissue diagnostics. Whole-slide scanners transform physical pathology slides into high-resolution digital images that can be reviewed remotely, integrated into information systems and analyzed by software. Adoption is likely to accelerate as institutions face pathology workforce constraints and attempt to share subspecialty expertise across hospital networks.

Artificial intelligence is also progressing from simple detection toward risk stratification and prognosis. FDA-authorized cancer-oriented software now spans radiology and pathology, including tools designed to evaluate mammography, prostate MRI and digitized tissue images. Over the forecast period, algorithm performance alone will not define competitive success. Integration with scanner hardware, PACS, laboratory information systems, electronic health records and clinician workflow will become equally important.

Intraoperative cancer detection is an emerging interface between diagnosis and surgery. Fluorescence-based visualization and optical scanning technologies can help identify residual malignant tissue or visualize tissue microstructure during procedures. These platforms create a new diagnostic-device opportunity because they shift diagnostic information closer to the point of intervention.

 

Segmentation Insights

The U.S. Cancer Diagnostic Devices Market is segmented on the basis of product category, diagnostic modality, cancer type, end user, and region.

 

By Product Category

Diagnostic Imaging Systems

Diagnostic imaging systems represent the largest product category by value. The segment includes oncology-relevant CT systems, MRI systems, PET and PET/CT platforms, mammography and digital breast tomosynthesis equipment, ultrasound platforms and associated image-guidance technologies. Cancer diagnosis accounts for substantial utilization of advanced imaging because scans are required during detection, staging, biopsy guidance and surveillance.

Replacement demand is becoming increasingly performance driven. Health systems are prioritizing faster acquisition, improved image quality, lower dose, AI reconstruction, advanced detector technologies and software upgrades capable of extending the clinical life of installed equipment. Premium growth is expected around photon-counting CT, spectral imaging, digital breast tomosynthesis, high-field MRI, PET/CT and AI-enabled imaging workflows.

Biopsy and Tissue-Acquisition Devices

Biopsy systems form a recurring procedure-driven category encompassing core biopsy systems, aspiration devices, biopsy needles, vacuum-assisted breast biopsy, stereotactic devices, endoscopic forceps, image-guided biopsy systems and specialized access technologies. The category benefits from the continuing requirement for tissue confirmation before most cancer treatment decisions.

Future growth will favor precision biopsy technologies that improve lesion targeting and specimen adequacy. Robotic bronchoscopy, navigation-assisted pulmonary biopsy, fusion-guided prostate biopsy and advanced breast-biopsy platforms should gain share within high-value procedures.

Endoscopy and Visualization Devices

Cancer-oriented endoscopy and visualization equipment includes colonoscopes, gastroscopes, bronchoscopes, cystoscopes and other visualization platforms used to detect suspicious tissue. High-definition imaging, narrow-band visualization, AI-assisted lesion detection, fluorescence imaging and disposable or semi-disposable components are reshaping this market.

Gastrointestinal oncology remains the most significant demand center because colonoscopy combines screening, lesion identification, biopsy and polyp removal. Pulmonary and urologic applications are also gaining strategic value as imaging and navigation technologies improve.

Pathology and Digital Pathology Systems

This category includes whole-slide scanners, pathology imaging workstations, digital displays, slide-management systems, automated tissue-processing equipment and cancer-oriented pathology software. Digital pathology remains smaller than imaging by absolute revenue but is expected to be one of the faster-growing product categories.

Hospitals are increasingly evaluating pathology digitization as an enterprise infrastructure investment rather than merely a laboratory equipment upgrade. The ability to share slides between facilities, obtain remote specialist review and deploy AI algorithms creates significant network value.

Molecular and Oncology IVD Instruments

Oncology-oriented IVD instrumentation includes PCR platforms, sequencing systems, cytometry equipment, immunohistochemistry systems and other analyzers used to generate diagnostic or biomarker information. While stand-alone reagent revenue is outside the narrow device-only scope of this report, the installed instrument base represents an important component of cancer diagnostic-device demand.

Growth will be supported by precision oncology, companion diagnostics, genomic profiling and increasing integration between anatomic pathology and molecular data.

 

By Diagnostic Modality

Medical Imaging

Medical imaging is the dominant modality because breast, lung, brain, liver, pancreatic, kidney, prostate and other cancers require imaging at multiple points in the diagnostic pathway. CT remains the workhorse modality for many tumor types, while MRI carries high value in breast, prostate, neurological, musculoskeletal and selected abdominal cancers. PET adds metabolic information that can materially influence staging and recurrence assessment.

Tissue Biopsy

Tissue biopsy remains the clinical standard for definitive diagnosis across most solid tumors. The economic opportunity is shifting toward image-guided and minimally invasive approaches that obtain representative tissue while reducing procedural burden. Device companies able to combine access, navigation, imaging and tissue acquisition within one workflow have a competitive advantage.

Endoscopic and Visual Diagnosis

Endoscopic detection is central to colorectal, gastric, esophageal, pulmonary, bladder and other cancers. AI-assisted visual detection is becoming increasingly relevant because it can act during the procedure rather than after image acquisition. This capability supports real-time physician decision-making and may increase detection of subtle lesions.

Digital and Computational Pathology

Digital pathology transforms histology into a software-addressable diagnostic environment. This allows remote collaboration, quantitative measurement, workflow prioritization and AI-supported analysis. Adoption will accelerate as laboratories digitize high-volume oncology workflows and health systems seek greater pathology capacity without proportional increases in specialist staffing.

Molecular and Biomarker-Based Instrumentation

This modality supports tumor classification, companion diagnostics, hereditary-risk testing and precision treatment selection. The instrumentation layer benefits from increasing biomarker complexity. Over the forecast period, molecular platforms will increasingly connect with pathology images and clinical data rather than operate as isolated laboratory systems.

 

By Cancer Type

Breast Cancer

Breast cancer is the largest cancer-specific diagnostic-device opportunity. The U.S. was expected to record more than 300,000 new invasive breast cancer cases among women in 2025, while the national mammography infrastructure performs tens of millions of examinations annually. Mammography, digital breast tomosynthesis, ultrasound, MRI, stereotactic biopsy, vacuum-assisted biopsy and pathology platforms all participate in the diagnostic pathway.

Lung Cancer

Lung cancer creates strong demand for CT, PET/CT, bronchoscopy, navigation platforms, robotic biopsy systems and pathology technologies. Earlier diagnosis is particularly important because survival outcomes differ materially by stage. Growth in low-dose CT screening is expanding the pool of suspicious nodules requiring advanced diagnostic evaluation.

Colorectal Cancer

Colorectal cancer diagnosis depends heavily on endoscopy, pathology, CT, biopsy and related visualization technology. Screening recommendations now include younger adults than historically, expanding the eligible population. Colonoscopy remains strategically important because it functions as both a diagnostic procedure and a cancer-prevention intervention through polyp removal.

Prostate Cancer

Prostate cancer diagnostics is shifting toward multiparametric MRI, fusion-guided biopsy, targeted tissue acquisition, advanced ultrasound and digital pathology. Better lesion localization can reduce unnecessary sampling and support more clinically relevant tissue acquisition. AI interpretation of prostate MRI and pathology may add another high-growth layer.

Other Cancers

The remaining category includes melanoma, cervical, uterine, ovarian, pancreatic, liver, kidney, bladder, thyroid, brain, head-and-neck and hematologic malignancies. Although individual device pathways differ significantly, collectively these cancers create substantial demand for imaging, visualization, pathology and laboratory instrumentation.

 

By End User

Hospitals and Integrated Health Systems

Hospitals represent the largest end-user group because they combine radiology, pathology, surgery, endoscopy, oncology and laboratory infrastructure. Large systems increasingly negotiate enterprise agreements covering multiple imaging and diagnostic platforms. Vendor selection is influenced by equipment utilization, uptime guarantees, cybersecurity, interoperability, service contracts, software upgrade paths and standardized clinical workflows.

Cancer Centers and Academic Medical Centers

Comprehensive cancer centers and academic institutions remain disproportionately important for advanced diagnostic adoption. These centers frequently evaluate new imaging, biopsy, pathology and AI technologies before community diffusion. They also influence clinical protocols, conduct device trials and provide specialist training.

Diagnostic Imaging and Breast Centers

Independent imaging networks and breast centers represent a high-volume end-user segment. Their economics depend heavily on patient throughput and equipment utilization. Technologies that shorten examination time, improve workflow automation or increase diagnostic confidence can therefore deliver measurable return on investment.

Specialty Clinics and Ambulatory Centers

Gastroenterology, pulmonology, urology and other specialty practices increasingly perform cancer-related diagnostic procedures outside traditional inpatient environments. This supports demand for endoscopy systems, ultrasound, biopsy equipment, navigation technologies and compact diagnostic platforms.

Pathology and Reference Laboratories

Pathology laboratories are becoming major buyers of scanners, automated laboratory systems, digital workstations and oncology-oriented IVD instruments. Networked pathology organizations can gain particularly strong economic benefits from digitization because cases can be routed electronically to subspecialists irrespective of location.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Cancer Diagnostic Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional demand varies according to cancer incidence, population size, age distribution, screening participation, health-system concentration, oncology specialist density, academic medical-center presence, outpatient imaging capacity and adoption of advanced technology.

The South represents the largest regional market, while the West is expected to record the fastest growth through 2035. The Northeast remains particularly strong in academic oncology, advanced pathology and premium imaging, while the Midwest provides a large and stable base of hospital and community cancer diagnostics.

South

The South accounted for an estimated USD 11.85 billion in 2025 and is projected to reach approximately USD 29.05 billion by 2035, representing an estimated regional CAGR of about 9.38%. Its scale is driven by population growth, large Medicare populations, substantial cancer burden and rapid expansion of hospital and outpatient diagnostic networks.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Tennessee, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, Kentucky, West Virginia, Delaware and the District of Columbia within the report’s regional mapping.

Texas is one of the country’s most important diagnostic-device markets. Approximately 150,870 new cancer cases were projected in Texas during 2025. Houston, Dallas-Fort Worth, Austin and San Antonio support major health systems, academic oncology programs, breast centers, pathology laboratories and imaging networks. Texas is especially attractive for manufacturers of high-throughput imaging systems, biopsy technologies, digital pathology and oncology laboratory instrumentation.

Florida represents another exceptionally large cancer diagnostics opportunity, with approximately 171,960 expected new cases in 2025. Its older population creates strong utilization of mammography, CT, PET/CT, endoscopy, prostate diagnostics and pathology. Florida is particularly attractive for outpatient imaging and cancer-center networks because patients frequently move through multisite diagnostic pathways.

North Carolina, with roughly 71,320 projected new cases, combines growing population centers with sophisticated academic institutions and regional health systems. The Research Triangle and major provider systems support adoption of AI, pathology digitization, molecular instrumentation and advanced imaging.

Georgia, with approximately 66,210 projected cases, is another fast-growing market. Atlanta acts as a major referral and imaging hub for surrounding Southeastern states. Cancer diagnostic demand is supported by large metropolitan health systems while rural portions of the state create a separate need for distributed imaging and telepathology.

Virginia was expected to record approximately 50,510 new cases, supporting sizable demand for breast imaging, CT, MRI, pathology and gastrointestinal cancer diagnostics. Maryland, Tennessee and South Carolina also represent important state opportunities because of major regional oncology programs and substantial cancer case volumes.

States including Mississippi, Louisiana, Alabama, Kentucky, Arkansas and West Virginia have significant cancer burdens but comparatively greater access challenges. Manufacturers may therefore encounter a two-tiered market: premium diagnostic platforms concentrated in large referral centers and scalable, lower-complexity or remotely supported solutions needed across rural communities.

The South should remain the largest regional market through 2035 as population growth, aging demographics, cancer incidence and hospital-system expansion reinforce demand.

West

The West represented approximately USD 7.27 billion in 2025 and is expected to reach nearly USD 19.20 billion by 2035, producing the fastest estimated regional CAGR of approximately 10.20%.

The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the most important state market in the West and the largest individual cancer market nationally by projected case volume. Approximately 199,980 new cancer diagnoses were expected in 2025. California combines enormous procedure demand with major academic medical centers, integrated health systems, imaging groups, pathology laboratories, medtech companies and AI developers.

California has particular strategic relevance for early adoption of AI-enabled imaging, digital pathology, advanced PET, molecular diagnostic instrumentation, robotic biopsy and connected diagnostic platforms. Large systems can also support enterprise deployment across multiple facilities, creating high-value contracting opportunities.

Arizona had approximately 42,560 projected new cancer cases in 2025. Population growth and aging demographics are strengthening demand for breast imaging, prostate diagnostics, CT, PET, pathology and endoscopy. Phoenix and other major population centers are becoming increasingly attractive to national imaging and specialty networks.

Washington was expected to record approximately 46,500 new cancer cases, making it another significant Western market. Large integrated healthcare organizations and research-oriented institutions support sophisticated imaging and digital workflow adoption.

Colorado, with approximately 29,020 projected cases, benefits from strong urban provider infrastructure and health systems that are receptive to digital medicine and value-based care models. Oregon, Nevada and Utah provide additional high-growth opportunities as their populations expand and outpatient diagnostic infrastructure grows.

The West should gain national market share because the region combines demographic growth with unusually high digital-health adoption. Technologies based on cloud pathology, AI image analysis, advanced imaging reconstruction and software-defined workflow may penetrate Western health systems faster than the national average.

Northeast

The Northeast represented approximately USD 6.95 billion in 2025 and is forecast to reach approximately USD 16.15 billion by 2035, corresponding to an estimated CAGR of about 8.80%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, New Hampshire, Vermont and Rhode Island.

New York is the region’s largest market with approximately 123,430 projected new cancer cases in 2025. New York City and the broader state contain major academic hospitals, cancer institutes, imaging centers and pathology networks. Premium imaging technologies, digital pathology, molecular instrumentation and complex biopsy systems have strong adoption potential.

Pennsylvania, with approximately 90,240 projected cases, provides another substantial procedure base. Philadelphia and Pittsburgh contain sophisticated academic and integrated health systems, while the state’s broader community-hospital network supports substantial recurring demand for imaging, breast diagnostics, pathology and endoscopy.

New Jersey had approximately 59,840 projected new cases, benefiting from high population density and proximity to major oncology research and pharmaceutical ecosystems. Massachusetts, with approximately 44,000 projected cases, is disproportionately influential because Boston’s academic hospitals frequently serve as early evaluators of advanced imaging, pathology and AI technologies.

Connecticut, Rhode Island, New Hampshire, Maine and Vermont are smaller absolute markets but maintain relatively advanced diagnostic infrastructure. The Northeast also has high specialist density, allowing early adoption of technologies requiring subspecialty expertise.

Regional growth is expected to remain slightly below the West because population growth is slower and imaging infrastructure is comparatively mature. However, the Northeast should remain one of the most valuable regions per diagnostic procedure because of complex case mix, academic referral patterns and premium technology adoption.

Midwest

The Midwest accounted for an estimated USD 5.79 billion in 2025 and is projected to reach approximately USD 12.98 billion by 2035, representing an estimated CAGR of 8.41%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

Illinois recorded an estimated 78,870 new cancer cases in 2025, making it the largest cancer diagnostic market in the Midwest. Chicago supports a dense network of academic hospitals, cancer centers, imaging groups and pathology laboratories.

Ohio, with approximately 77,010 projected cases, is another major diagnostic-device market with significant hospital and oncology infrastructure across Cleveland, Columbus, Cincinnati and other metropolitan areas.

Michigan had approximately 66,040 projected cases, providing sustained demand for CT, MRI, PET, mammography, pathology, endoscopy and biopsy technology. Minnesota, with roughly 37,650 projected cases, has strategic significance beyond its population because of its strong medtech ecosystem and sophisticated tertiary-care institutions.

Wisconsin, Indiana and Missouri generate substantial procedure volumes through large community and integrated hospital systems. Iowa, Kansas, Nebraska, North Dakota and South Dakota represent smaller markets but create opportunities for telepathology, cloud-enabled diagnostic workflows, mobile imaging and technologies capable of supporting regional referral models.

The Midwest is unlikely to match Western growth rates, but its large established health-system infrastructure provides dependable replacement demand. Vendors that combine strong service coverage, capital flexibility, enterprise pricing and long equipment life cycles can compete effectively in this region.

 

Key Market Players

The U.S. Cancer Diagnostic Devices competitive landscape includes diversified imaging manufacturers, pathology companies, biopsy-device specialists, endoscopy companies, molecular-diagnostic instrument manufacturers and rapidly growing AI-enabled diagnostic companies.

Major relevant participants include GE HealthCare, Siemens Healthineers, Philips, Hologic, Roche Diagnostics, Abbott Laboratories, Danaher Corporation, Beckman Coulter, Leica Biosystems, Becton Dickinson, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Fujifilm Healthcare, Canon Medical Systems, Olympus Corporation, Boston Scientific, Medtronic, Intuitive Surgical, Carl Zeiss Meditec, Bruker Corporation, Guardant Health, Exact Sciences and QuidelOrtho.

GE HealthCare, Siemens Healthineers, Philips, Canon Medical and Fujifilm compete across high-value imaging platforms used extensively in oncology. Their competitive positions increasingly depend on detector performance, workflow software, AI integration, service contracts, enterprise interoperability and the ability to support multi-modality oncology imaging.

Hologic maintains particular strategic importance in breast cancer diagnostics through mammography, digital breast tomosynthesis, biopsy and women’s diagnostic technologies.

Roche, Abbott, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent, Danaher and BD participate extensively in oncology laboratory and pathology workflows. Leica Biosystems is particularly important to the transition toward digital pathology and whole-slide imaging.

Olympus, Boston Scientific and related procedural-device companies participate through endoscopy, biopsy and visualization workflows. Intuitive Surgical is increasingly relevant to diagnostic oncology through robotic bronchoscopy and lesion-access technologies.

Competition through 2035 will be increasingly platform based. Manufacturers with broad hardware portfolios can bundle imaging, workflow software, service and AI. More focused competitors can win by addressing specific clinical problems such as peripheral lung nodule access, digital pathology bottlenecks, high-risk mammography interpretation or lesion-targeted biopsy.

Hospital procurement will increasingly reward vendors that demonstrate not simply better image quality but measurable improvement in diagnostic throughput, repeat-procedure reduction, clinician productivity and patient conversion from screening to treatment.

 

Recent Developments

Recent U.S. regulatory activity illustrates the speed at which cancer diagnostic-device technology is evolving.

During 2024, the FDA authorized 76 oncology devices, including 27 in vitro diagnostic devices and approximately 40 radiation oncology and diagnostic imaging devices. Important diagnostic developments included clearance of digital pathology systems and authorization of newer cancer-visualization technologies.

The Lumicell Direct Visualization System received FDA approval for fluorescence-assisted detection of cancerous tissue within the breast surgical cavity, demonstrating how diagnostic visualization is expanding into intraoperative workflows.

The FDA also granted De Novo authorization to DermaSensor, an AI-supported elastic scattering spectroscopy device intended to assist in evaluating malignant skin lesions, including melanoma, squamous cell carcinoma and basal cell carcinoma. The authorization illustrates the emerging opportunity for point-of-care optical cancer assessment.

Digital pathology advanced through clearances involving whole-slide imaging systems, interoperable software and diagnostic displays. The movement toward DICOM-based interoperability is particularly strategically relevant because hospitals increasingly want pathology images to function more like radiology data inside enterprise information infrastructure.

Cancer-oriented AI continued expanding during 2025. FDA activity included authorization of AI-based radiology and pathology technologies. Siemens’ Prostate MR AI received U.S. clearance in March 2025 as radiological computer-assisted detection and diagnosis software for lesions suspicious for cancer.

In July 2025, the FDA granted De Novo authorization to ArteraAI Prostate, a pathology software algorithm device designed to analyze digital images for prostate cancer prognosis. This development shows how the cancer diagnostic-device market is extending beyond detection toward computational assessment of disease biology and expected outcomes.

FDA oncology-device activity accelerated further during 2025, with more than 90 oncology devices authorized, including 26 IVD devices and 63 radiation oncology and diagnostic radiology devices. This authorization volume reflects a high level of innovation entering the U.S. oncology ecosystem.

AI-enabled breast-risk technology also continued developing. New software platforms are moving beyond detection of an existing lesion toward risk prediction using imaging already obtained during routine screening. This could increase the strategic value of mammography datasets while creating opportunities for software-driven risk stratification.

Robotic bronchoscopy and navigational lung biopsy remain another major innovation cycle. Growing low-dose CT screening creates more identified pulmonary nodules, increasing the need for technologies capable of accessing small peripheral lesions and obtaining diagnostically useful samples.

The broader competitive direction is therefore clear. Cancer diagnostics is shifting from independent imaging, biopsy and pathology steps toward an integrated sequence in which suspicious findings are identified algorithmically, sampled with image or robotic guidance, digitized in pathology and combined with molecular information for treatment planning.

 

Conclusion

The U.S. Cancer Diagnostic Devices Market Size & Share is positioned for substantial expansion from approximately USD 31.86 billion in 2025 to USD 77.38 billion by 2035, representing a projected 9.28% CAGR during 2026–2035.

The underlying demand case is exceptionally durable. More than two million Americans are being diagnosed with cancer annually, while screening, imaging, biopsy, pathology and surveillance generate diagnostic-device utilization far beyond initial case counts. The market therefore benefits from both disease incidence and the increasing intensity of diagnostic work performed for each patient.

Imaging will remain the largest value pool, but faster growth is expected in robotic and navigational biopsy, digital pathology, AI-assisted diagnosis, advanced breast imaging, computational pathology, fluorescence visualization and connected diagnostic workflow platforms.

Breast cancer will remain one of the most commercially important disease categories because of the scale of routine mammography infrastructure. Lung cancer represents a major emerging device opportunity as screening creates more early pulmonary findings requiring advanced imaging and targeted tissue acquisition. Colorectal cancer will sustain endoscopy demand, while prostate cancer increasingly supports MRI-guided and computational diagnostic technologies.

Regionally, the South will remain the largest market because of population scale and cancer burden. The West should grow fastest because of demographic expansion and rapid adoption of digital and AI-enabled platforms. The Northeast will continue to influence premium technology adoption through leading academic centers, while the Midwest will remain a stable and strategically important replacement market.

California, Florida, Texas, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, New Jersey, Michigan, Virginia, Washington, Massachusetts and Arizona represent particularly important state-level opportunities because of their cancer case volumes, provider infrastructure and concentration of diagnostic procedures.

For device manufacturers, investors and market-entry teams, the principal opportunity is no longer simply supplying more diagnostic equipment. The highest-value competitive positions will emerge at the points where hospitals experience diagnostic friction: suspicious findings that are difficult to characterize, lesions that are difficult to reach, tissue samples that are nondiagnostic, pathology queues that delay treatment, imaging workloads that exceed physician capacity, and diagnostic data that remain disconnected across departments.

The next decade of the U.S. cancer diagnostic-device market will therefore be defined by technologies that reduce the time between screening abnormality and actionable diagnosis. Companies able to integrate precision hardware, AI, workflow software, evidence generation and hospital economics into a coherent diagnostic platform will be best positioned to capture the market’s premium growth.

 

TABLE OF CONTENT

1. U.S. Cancer Diagnostic Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Analytical Frameworks & Forecasting Models
1.3.6. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Cancer Diagnostic Device Manufacturers
1.6.2. Imaging Equipment and Component Suppliers
1.6.3. Biopsy and Tissue-Acquisition Device Manufacturers
1.6.4. Pathology and Molecular Diagnostic Instrument Companies
1.6.5. Hospitals and Integrated Delivery Networks
1.6.6. Comprehensive Cancer Centers and Academic Medical Centers
1.6.7. Diagnostic Imaging and Breast Imaging Centers
1.6.8. Pathology and Reference Laboratories
1.6.9. Gastroenterology, Pulmonology, Urology and Other Specialty Practices
1.6.10. Group Purchasing Organizations and Distributors
1.6.11. Payers, FDA, CMS and Clinical Decision-Makers

What this section provides: This section defines the market boundary, device categories, study scope, methodology, assumptions and stakeholder ecosystem used to measure and validate the U.S. Cancer Diagnostic Devices Market.

2. U.S. Cancer Diagnostic Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. High-Growth Opportunity Areas
2.9.1. AI-Assisted Cancer Imaging
2.9.2. Digital and Computational Pathology
2.9.3. Robotic and Navigational Biopsy
2.9.4. Advanced Breast Imaging and Image-Guided Biopsy
2.9.5. Lung Cancer Screening and Peripheral Nodule Diagnosis
2.9.6. Oncology Molecular Diagnostic Instrumentation

What this section provides: This section provides decision-makers with a concise view of market size, historical development, forecast growth, competitive intensity and the cancer diagnostic technologies expected to create the strongest value pools through 2035.

3. U.S. Cancer Diagnostic Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Aging Population
3.1.2. Expansion of Cancer Screening Programs
3.1.3. Growing Importance of Early-Stage Cancer Detection
3.1.4. Increasing Utilization of Advanced Diagnostic Imaging
3.1.5. Expansion of Image-Guided and Minimally Invasive Biopsy
3.1.6. Accelerating Digital Pathology Adoption
3.1.7. Growing Integration of AI into Radiology and Pathology
3.1.8. Increasing Precision Oncology and Biomarker Testing
3.1.9. Expansion of Outpatient Cancer Diagnostic Infrastructure
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Diagnostic Equipment
3.2.2. Reimbursement Pressure and Coverage Variability
3.2.3. Radiologist, Pathologist and Specialist Workforce Constraints
3.2.4. Complex FDA Regulatory Requirements
3.2.5. AI Validation, Liability and Clinical Adoption Concerns
3.2.6. Interoperability and Data Integration Challenges
3.2.7. Cybersecurity Risk Across Connected Diagnostic Infrastructure
3.3. Opportunities and Their Impact Analysis
3.3.1. Artificial Intelligence-Based Cancer Detection
3.3.2. Whole-Slide Imaging and Digital Pathology Transformation
3.3.3. Robotic Bronchoscopy and Navigational Lung Biopsy
3.3.4. Photon-Counting and Spectral CT Adoption
3.3.5. Contrast-Enhanced Mammography and Advanced Breast Imaging
3.3.6. AI-Assisted Endoscopic Cancer Detection
3.3.7. Expansion of Community and Rural Diagnostic Access
3.3.8. Integrated Radiology-Pathology-Molecular Diagnostic Platforms
3.4. Challenges and Their Impact Analysis
3.4.1. Diagnostic Workflow Fragmentation
3.4.2. Capital Budget Competition Inside U.S. Health Systems
3.4.3. Long Equipment Replacement Cycles
3.4.4. False Positives and Diagnostic Overutilization Risk
3.4.5. Clinical Evidence Requirements for AI-Based Technologies
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Cancer Diagnostic Clinical Workflow Economics Analysis
3.7. Diagnostic Turnaround Time and Patient Leakage Analysis
3.8. Hospital Capital Procurement Behavior Analysis
3.9. Cancer Screening-to-Diagnosis Conversion Analysis

What this section provides: This section examines the clinical, technological, economic and operational forces influencing cancer diagnostic-device demand and helps clients identify growth catalysts, adoption barriers and execution risks.

4. U.S. Cancer Diagnostic Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitution
4.2.5. Competitive Rivalry
4.3. Cancer Diagnostic Device Pricing Trend Analysis, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Diagnostic Imaging Installed-Base and Replacement-Cycle Analysis
4.6. Impact of Digitalization on Oncology Diagnostics
4.7. Artificial Intelligence Adoption Landscape
4.8. FDA Regulatory Framework Analysis
4.8.1. 510(k) Clearance Pathway
4.8.2. De Novo Classification Pathway
4.8.3. Premarket Approval Pathway
4.8.4. Software as a Medical Device Considerations
4.8.5. AI/ML-Enabled Medical Device Regulatory Considerations
4.8.6. Oncology IVD and Companion Diagnostic Requirements
4.9. CMS Reimbursement and Coverage Landscape
4.10. Screening Reimbursement and Preventive-Care Coverage Analysis
4.11. Import/Export Restrictions & Tariff Impact
4.12. U.S. Government Cancer Initiatives and Screening Programs
4.13. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.15. Diagnostic Equipment Total Cost of Ownership Analysis
4.16. Cybersecurity and Healthcare Data Governance Landscape

What this section provides: This section provides a complete view of the regulatory, reimbursement, technology, pricing, supply-chain, digitalization and hospital-procurement environment influencing cancer diagnostic-device commercialization in the United States.

5. U.S. Cancer Diagnostic Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
5.2. Diagnostic Imaging Systems
5.2.1. Computed Tomography Systems
5.2.2. Magnetic Resonance Imaging Systems
5.2.3. PET and PET/CT Systems
5.2.4. Mammography Systems
5.2.5. Digital Breast Tomosynthesis Systems
5.2.6. Ultrasound Imaging Systems
5.2.7. Other Oncology Imaging Systems
5.3. Biopsy and Tissue-Acquisition Devices
5.3.1. Core Needle Biopsy Devices
5.3.2. Fine-Needle Aspiration Devices
5.3.3. Vacuum-Assisted Biopsy Systems
5.3.4. Stereotactic Biopsy Systems
5.3.5. Image-Guided Biopsy Devices
5.3.6. Robotic and Navigational Biopsy Systems
5.3.7. Biopsy Forceps and Other Tissue-Acquisition Devices
5.4. Endoscopy and Visualization Devices
5.4.1. Colonoscopy Systems
5.4.2. Gastroscopy Systems
5.4.3. Bronchoscopy Systems
5.4.4. Cystoscopy Systems
5.4.5. Advanced Visualization and Spectral Imaging Systems
5.4.6. Fluorescence-Based Cancer Visualization Systems
5.4.7. AI-Assisted Endoscopic Visualization Platforms
5.5. Pathology and Digital Pathology Systems
5.5.1. Whole-Slide Imaging Scanners
5.5.2. Digital Pathology Workstations
5.5.3. Automated Tissue Processing Systems
5.5.4. Histology and Slide Preparation Equipment
5.5.5. AI-Assisted Pathology Platforms
5.5.6. Pathology Image Management Systems
5.6. Oncology IVD and Molecular Diagnostic Instruments
5.6.1. PCR and qPCR Instruments
5.6.2. Next-Generation Sequencing Instruments
5.6.3. Immunohistochemistry Systems
5.6.4. Flow Cytometry Systems
5.6.5. In Situ Hybridization Platforms
5.6.6. Other Oncology Laboratory Diagnostic Instruments

What this section provides: This section identifies the cancer diagnostic-device product categories expected to generate the largest revenue contribution and highlights faster-growing technologies across imaging, biopsy, visualization, pathology and molecular diagnostic instrumentation.

6. U.S. Cancer Diagnostic Devices Market – By Diagnostic Modality

6.1. Overview
6.1.1. Segment Share Analysis, By Diagnostic Modality, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
6.2. Medical Imaging-Based Diagnosis
6.2.1. CT-Based Cancer Diagnosis
6.2.2. MRI-Based Cancer Diagnosis
6.2.3. PET/PET-CT-Based Cancer Diagnosis
6.2.4. Mammography-Based Diagnosis
6.2.5. Ultrasound-Based Diagnosis
6.3. Tissue Biopsy-Based Diagnosis
6.3.1. Image-Guided Biopsy
6.3.2. Stereotactic Biopsy
6.3.3. Endoscopic Biopsy
6.3.4. Robotic and Navigational Biopsy
6.3.5. Conventional Needle-Based Biopsy
6.4. Endoscopic and Visual Diagnosis
6.4.1. Gastrointestinal Visualization
6.4.2. Pulmonary Visualization
6.4.3. Urologic Visualization
6.4.4. Fluorescence and Optical Visualization
6.4.5. AI-Assisted Visual Detection
6.5. Digital and Computational Pathology
6.5.1. Whole-Slide Imaging
6.5.2. Remote Digital Pathology
6.5.3. Quantitative Image Analysis
6.5.4. AI-Assisted Histopathology
6.5.5. Integrated Pathology Informatics
6.6. Molecular and Biomarker-Based Diagnosis
6.6.1. PCR-Based Diagnostics
6.6.2. Sequencing-Based Diagnostics
6.6.3. Immunohistochemistry-Based Diagnostics
6.6.4. Cytometry-Based Diagnostics
6.6.5. Companion Diagnostic Instrumentation

What this section provides: This section evaluates the diagnostic modalities through which U.S. cancers are detected, characterized and confirmed, helping clients understand how imaging, biopsy, pathology and molecular workflows compete and complement one another.

7. U.S. Cancer Diagnostic Devices Market – By Cancer Type

7.1. Overview
7.1.1. Segment Share Analysis, By Cancer Type, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
7.2. Breast Cancer
7.2.1. Screening Mammography
7.2.2. Digital Breast Tomosynthesis
7.2.3. Breast Ultrasound and MRI
7.2.4. Stereotactic and Vacuum-Assisted Breast Biopsy
7.2.5. Breast Digital Pathology and AI Diagnostics
7.3. Lung Cancer
7.3.1. Low-Dose CT Screening
7.3.2. Diagnostic CT and PET/CT
7.3.3. Bronchoscopy
7.3.4. Robotic and Navigational Lung Biopsy
7.3.5. Lung Cancer Pathology and Molecular Diagnostics
7.4. Colorectal Cancer
7.4.1. Colonoscopy
7.4.2. AI-Assisted Polyp Detection
7.4.3. Endoscopic Biopsy
7.4.4. Diagnostic Imaging
7.4.5. Colorectal Pathology and Molecular Diagnostics
7.5. Prostate Cancer
7.5.1. Multiparametric MRI
7.5.2. MRI-Ultrasound Fusion Imaging
7.5.3. Targeted Prostate Biopsy
7.5.4. Digital Pathology
7.5.5. AI-Based Prostate Cancer Diagnostics
7.6. Other Cancers
7.6.1. Skin Cancer and Melanoma
7.6.2. Cervical Cancer
7.6.3. Uterine and Ovarian Cancer
7.6.4. Pancreatic Cancer
7.6.5. Liver Cancer
7.6.6. Kidney Cancer
7.6.7. Bladder Cancer
7.6.8. Thyroid Cancer
7.6.9. Brain and Central Nervous System Cancer
7.6.10. Head and Neck Cancer
7.6.11. Hematologic Malignancies
7.6.12. Other Solid Tumors

What this section provides: This section measures diagnostic-device demand by major cancer indication and identifies disease areas where screening expansion, advanced imaging, biopsy innovation and digital pathology are creating the strongest commercial opportunities.

8. U.S. Cancer Diagnostic Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
8.2. Hospitals and Integrated Health Systems
8.2.1. Academic Hospitals
8.2.2. Large Integrated Delivery Networks
8.2.3. Community Hospitals
8.2.4. Regional Referral Hospitals
8.3. Cancer Centers and Academic Medical Centers
8.3.1. NCI-Designated Cancer Centers
8.3.2. Comprehensive Cancer Centers
8.3.3. University-Based Oncology Centers
8.3.4. Specialty Oncology Hospitals
8.4. Diagnostic Imaging and Breast Centers
8.4.1. Independent Diagnostic Imaging Centers
8.4.2. Breast Imaging Centers
8.4.3. Hospital-Affiliated Outpatient Imaging Centers
8.4.4. Multisite Imaging Networks
8.5. Specialty Clinics and Ambulatory Diagnostic Centers
8.5.1. Gastroenterology Practices
8.5.2. Pulmonology Practices
8.5.3. Urology Practices
8.5.4. Ambulatory Endoscopy Centers
8.5.5. Other Specialty Diagnostic Practices
8.6. Pathology and Reference Laboratories
8.6.1. Hospital Pathology Laboratories
8.6.2. Independent Reference Laboratories
8.6.3. Molecular Oncology Laboratories
8.6.4. Digital Pathology Networks

What this section provides: This section shows where cancer diagnostic equipment is purchased and deployed across the U.S. healthcare system and identifies the customer settings expected to drive capital expenditure, recurring device utilization and technology adoption.

9. U.S. Cancer Diagnostic Devices Market: Commercial & Procurement Analysis

9.1. Overview
9.2. Direct Hospital and Health System Procurement
9.3. Integrated Delivery Network Enterprise Contracting
9.4. Cancer Center Capital Equipment Procurement
9.5. Diagnostic Imaging Center Procurement Economics
9.6. Pathology Laboratory Equipment Procurement
9.7. Group Purchasing Organization Influence
9.8. Distributor and Specialty Supplier Role
9.9. OEM Direct Sales and Strategic Account Contracting
9.10. Software Subscription and AI Licensing Models
9.11. Equipment Leasing and Capital Financing Models
9.12. Service Contract and Maintenance Economics
9.13. Equipment Replacement and Upgrade Cycle Analysis
9.14. Hospital Value Analysis Committee Requirements
9.15. Clinical Evidence and Health-Economic Requirements
9.16. Total Cost of Ownership Analysis
9.17. Procurement Decision-Making Criteria
9.17.1. Clinical Accuracy
9.17.2. Diagnostic Yield
9.17.3. Patient Throughput
9.17.4. Workflow Efficiency
9.17.5. Interoperability
9.17.6. Cybersecurity
9.17.7. Equipment Uptime
9.17.8. Reimbursement Alignment
9.17.9. Service and Technical Support

What this section provides: This section explains how cancer diagnostic devices are evaluated, financed and purchased in the United States, including IDN standardization, GPO influence, capital-budget requirements, AI licensing and total-cost-of-ownership considerations.

10. U.S. Cancer Diagnostic Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Cancer Incidence and Screening Analysis
10.1.4. Regional Hospital, Cancer Center and Diagnostic Infrastructure Analysis
10.1.5. Regional Technology Adoption Analysis
10.1.6. Regional Reimbursement and Procurement Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Cancer Diagnostic Device Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Cancer Incidence, Screening and Diagnostic Infrastructure Analysis
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Cancer Diagnostic Device Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Cancer Incidence, Screening and Diagnostic Infrastructure Analysis
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Cancer Diagnostic Device Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Cancer Incidence, Screening and Diagnostic Infrastructure Analysis
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.24. Delaware
10.4.24.1. Overview
10.4.24.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.24.3. Delaware Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.4.24.4. Delaware Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.24.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Cancer Diagnostic Device Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Cancer Incidence, Screening and Diagnostic Infrastructure Analysis
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Diagnostic Modality, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 U.S. states, helping clients identify cancer-incidence concentrations, screening infrastructure, diagnostic capacity, technology-adoption hotspots and priority commercial territories.

11. U.S. Cancer Diagnostic Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.2.1. Product Portfolio Breadth
11.2.2. Oncology Diagnostic Technology Positioning
11.2.3. Installed Base and Customer Reach
11.2.4. AI and Digital Capability
11.2.5. FDA Regulatory Momentum
11.2.6. U.S. Commercial and Service Infrastructure
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Company Profiles
11.4.1. GE HealthCare
11.4.2. Siemens Healthineers
11.4.3. Philips
11.4.4. Hologic, Inc.
11.4.5. Roche Diagnostics
11.4.6. Danaher Corporation
11.4.7. Leica Biosystems
11.4.8. Becton, Dickinson and Company
11.4.9. Thermo Fisher Scientific
11.4.10. Illumina, Inc.
11.4.11. QIAGEN
11.4.12. Agilent Technologies
11.4.13. Fujifilm Healthcare
11.4.14. Canon Medical Systems
11.4.15. Olympus Corporation
11.4.16. Boston Scientific Corporation
11.4.17. Medtronic
11.4.18. Intuitive Surgical
11.4.19. Bruker Corporation
11.4.20. QuidelOrtho Corporation
11.4.21. Bio-Rad Laboratories
11.4.22. Revvity, Inc.
11.4.23. Paige
11.4.24. PathAI
11.4.25. Exact Sciences Corporation

Note: Each company profile will include company overview, relevant cancer diagnostic-device portfolio, U.S. market strategy, financial and commercial positioning, clinical and technology pipeline, FDA/regulatory updates, partnerships, acquisitions, AI/digital capabilities and recent developments.

What this section provides: This section provides competitor benchmarking, market-share visibility, product and platform positioning, digital and AI capability assessment, innovation direction and strategic intelligence on leading cancer diagnostic-device companies operating in the United States.

12. U.S. Cancer Diagnostic Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. AI-Assisted Cancer Imaging
12.2.2. Digital and Computational Pathology
12.2.3. Robotic and Navigational Biopsy
12.2.4. Photon-Counting and Spectral CT
12.2.5. Advanced PET Imaging
12.2.6. Contrast-Enhanced Mammography
12.2.7. AI-Assisted Endoscopy
12.2.8. Fluorescence and Optical Cancer Detection
12.2.9. Integrated Molecular and Imaging Diagnostics
12.3. Future of Cancer Screening Technology
12.4. Evolution of Radiology-Pathology-Molecular Integration
12.5. Diagnostic Workflow Automation Outlook
12.6. Emerging Business Models
12.7. Business Opportunities for Startups and Existing Players
12.8. Investment Prioritization Matrix
12.9. Market White-Space Analysis
12.10. Technology Adoption Roadmap, 2026–2035

What this section provides: This section prepares clients for future technology shifts, diagnostic workflow transformation, changing market structure and investment opportunities expected to reshape U.S. cancer diagnostics through 2035.

13. U.S. Cancer Diagnostic Devices Market: Strategic Recommendations

13.1. Recommendations for Cancer Diagnostic Device Manufacturers
13.2. Recommendations for Diagnostic Imaging Companies
13.3. Recommendations for Pathology and Molecular Diagnostic Companies
13.4. Recommendations for Hospitals and Integrated Health Systems
13.5. Recommendations for Comprehensive Cancer Centers
13.6. Recommendations for Diagnostic Imaging and Pathology Networks
13.7. Recommendations for Investors and Private Equity Firms
13.8. Recommendations for Distributors and Channel Partners
13.9. Recommendations for New Entrants and Startups
13.10. U.S. Market Entry Strategy
13.11. Go-to-Market Strategy Considerations
13.12. Product Positioning and Portfolio Expansion Guidance
13.13. Hospital Evidence-Generation Strategy
13.14. AI Commercialization Strategy
13.15. Partnership, Licensing and Acquisition Opportunity Analysis

What this section provides: This section converts the report’s market intelligence into actionable recommendations for product strategy, U.S. market entry, hospital adoption, portfolio development, channel expansion, investment prioritization and competitive differentiation.

14. U.S. Cancer Diagnostic Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition Limitation
14.3. Data Use Limitation
14.4. Forecasting Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Device, Instrument, Consumable and Service Boundary Disclaimer
14.8. Regulatory and Reimbursement Information Disclaimer

What this section provides: This section clarifies the report’s scope, market-measurement boundaries, data-use limitations, forecasting assumptions, regulatory considerations and legal conditions applicable to the U.S. Cancer Diagnostic Devices Market.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Cancer Diagnostic Devices Market: Market Definition and Scope
TABLE 3: U.S. Cancer Diagnostic Devices Market: Research Methodology Framework
TABLE 4: U.S. Cancer Diagnostic Devices Market: Key Assumptions
TABLE 5: U.S. Cancer Diagnostic Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Cancer Diagnostic Devices Market: Stakeholder Analysis
TABLE 7: U.S. Cancer Diagnostic Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Cancer Diagnostic Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Cancer Diagnostic Devices Market: Market Attractiveness Index
TABLE 10: U.S. Cancer Diagnostic Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Cancer Diagnostic Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Cancer Diagnostic Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Cancer Diagnostic Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Cancer Diagnostic Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Cancer Diagnostic Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Cancer Diagnostic Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Cancer Diagnostic Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Cancer Diagnostic Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Cancer Diagnostic Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Cancer Diagnostic Devices Market: Cancer Diagnostic Clinical Workflow Economics Matrix
TABLE 21: U.S. Cancer Diagnostic Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 22: U.S. Cancer Diagnostic Devices Market: Screening-to-Diagnosis Conversion Analysis
TABLE 23: U.S. Cancer Diagnostic Devices Market: PESTEL Analysis
TABLE 24: U.S. Cancer Diagnostic Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Cancer Diagnostic Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 26: U.S. Cancer Diagnostic Devices Market: Value Chain Analysis
TABLE 27: U.S. Cancer Diagnostic Devices Market: Supply Chain Analysis
TABLE 28: U.S. Cancer Diagnostic Devices Market: Diagnostic Imaging Installed-Base and Replacement-Cycle Analysis
TABLE 29: U.S. Cancer Diagnostic Devices Market: Artificial Intelligence Adoption Landscape
TABLE 30: U.S. Cancer Diagnostic Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Cancer Diagnostic Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Cancer Diagnostic Devices Market: Cancer Screening Reimbursement Landscape
TABLE 33: U.S. Cancer Diagnostic Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. Cancer Diagnostic Devices Market: U.S. Government Cancer Initiatives and Screening Programs
TABLE 35: U.S. Cancer Diagnostic Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 36: U.S. Cancer Diagnostic Devices Market: Diagnostic Equipment Total Cost of Ownership Analysis
TABLE 37: U.S. Cancer Diagnostic Devices Market: Product Category Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Category
TABLE 39: U.S. Cancer Diagnostic Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 40: U.S. Cancer Diagnostic Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 41: Diagnostic Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: Biopsy and Tissue-Acquisition Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Endoscopy and Visualization Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Pathology and Digital Pathology Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Oncology IVD and Molecular Diagnostic Instruments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Cancer Diagnostic Devices Market: Diagnostic Modality Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Diagnostic Modality
TABLE 48: U.S. Cancer Diagnostic Devices Market, by Diagnostic Modality, 2021–2035 (US$ Billion)
TABLE 49: U.S. Cancer Diagnostic Devices Market: Segment Share Analysis, by Diagnostic Modality, 2025 & 2035 (%)
TABLE 50: Medical Imaging-Based Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Tissue Biopsy-Based Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Endoscopic and Visual Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Digital and Computational Pathology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Molecular and Biomarker-Based Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Cancer Diagnostic Devices Market: Cancer Type Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by Cancer Type
TABLE 57: U.S. Cancer Diagnostic Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 58: U.S. Cancer Diagnostic Devices Market: Segment Share Analysis, by Cancer Type, 2025 & 2035 (%)
TABLE 59: Breast Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Lung Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Colorectal Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Prostate Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Other Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Cancer Diagnostic Devices Market: End User Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by End User
TABLE 66: U.S. Cancer Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 67: U.S. Cancer Diagnostic Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 68: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Cancer Centers and Academic Medical Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Diagnostic Imaging and Breast Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Specialty Clinics and Ambulatory Diagnostic Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Pathology and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Cancer Diagnostic Devices Market: Commercial & Procurement Landscape
TABLE 74: U.S. Cancer Diagnostic Devices Market: IDN and Enterprise Contracting Analysis
TABLE 75: U.S. Cancer Diagnostic Devices Market: GPO and Distributor Influence Analysis
TABLE 76: U.S. Cancer Diagnostic Devices Market: AI Licensing and Software Subscription Models
TABLE 77: U.S. Cancer Diagnostic Devices Market: Equipment Leasing and Capital Financing Models
TABLE 78: U.S. Cancer Diagnostic Devices Market: Service Contract and Maintenance Economics
TABLE 79: U.S. Cancer Diagnostic Devices Market: Equipment Replacement and Upgrade Cycle
TABLE 80: U.S. Cancer Diagnostic Devices Market: Procurement Decision-Making Criteria
TABLE 81: U.S. Cancer Diagnostic Devices Market: Regional Snapshot, 2025
TABLE 82: Segment Dashboard; Definition and Scope, by Geography
TABLE 83: U.S. Cancer Diagnostic Devices Market, by Geography, 2021–2035 (US$ Billion)
TABLE 84: U.S. Cancer Diagnostic Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 85: West Region U.S. Cancer Diagnostic Devices Market: Regional Overview and Trends
TABLE 86: West Region U.S. Cancer Diagnostic Devices Market: Cancer Incidence, Screening and Diagnostic Infrastructure
TABLE 87: West Region U.S. Cancer Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 88: West Region U.S. Cancer Diagnostic Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 89: West Region U.S. Cancer Diagnostic Devices Market, by Diagnostic Modality, 2021–2035 (US$ Billion)
TABLE 90: West Region U.S. Cancer Diagnostic Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Cancer Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 92: California Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Washington Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Arizona Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Colorado Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Oregon Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Utah Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Nevada Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: New Mexico Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Idaho Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Montana Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Wyoming Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Alaska Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Hawaii Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Northeast Region U.S. Cancer Diagnostic Devices Market: Regional Overview and Trends
TABLE 106: Northeast Region U.S. Cancer Diagnostic Devices Market: Cancer Incidence, Screening and Diagnostic Infrastructure
TABLE 107: Northeast Region U.S. Cancer Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region U.S. Cancer Diagnostic Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Cancer Diagnostic Devices Market, by Diagnostic Modality, 2021–2035 (US$ Billion)
TABLE 110: Northeast Region U.S. Cancer Diagnostic Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. Cancer Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 112: New York Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Massachusetts Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: New Jersey Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Pennsylvania Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Connecticut Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Maine Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Vermont Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: New Hampshire Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Rhode Island Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: South Region U.S. Cancer Diagnostic Devices Market: Regional Overview and Trends
TABLE 122: South Region U.S. Cancer Diagnostic Devices Market: Cancer Incidence, Screening and Diagnostic Infrastructure
TABLE 123: South Region U.S. Cancer Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 124: South Region U.S. Cancer Diagnostic Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 125: South Region U.S. Cancer Diagnostic Devices Market, by Diagnostic Modality, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Cancer Diagnostic Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. Cancer Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: Texas Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Florida Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Georgia Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: North Carolina Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Tennessee Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: South Carolina Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Alabama Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Mississippi Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Louisiana Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Arkansas Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Kentucky Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Oklahoma Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Virginia Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Maryland Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: West Virginia Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Delaware Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Midwest Region U.S. Cancer Diagnostic Devices Market: Regional Overview and Trends
TABLE 145: Midwest Region U.S. Cancer Diagnostic Devices Market: Cancer Incidence, Screening and Diagnostic Infrastructure
TABLE 146: Midwest Region U.S. Cancer Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 147: Midwest Region U.S. Cancer Diagnostic Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. Cancer Diagnostic Devices Market, by Diagnostic Modality, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region U.S. Cancer Diagnostic Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region U.S. Cancer Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 151: Illinois Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Ohio Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Michigan Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Minnesota Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Indiana Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Wisconsin Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Missouri Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Iowa Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Kansas Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Nebraska Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: North Dakota Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: South Dakota Cancer Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: U.S. Cancer Diagnostic Devices Market: Competitive Landscape Snapshot, 2025
TABLE 164: U.S. Cancer Diagnostic Devices Market: Key Company Market Share Analysis, 2025
TABLE 165: U.S. Cancer Diagnostic Devices Market: Company Positioning Matrix
TABLE 166: U.S. Cancer Diagnostic Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 167: U.S. Cancer Diagnostic Devices Market: AI and Digital Capability Benchmarking
TABLE 168: U.S. Cancer Diagnostic Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 169: GE HealthCare: Company Profile
TABLE 170: Siemens Healthineers: Company Profile
TABLE 171: Philips: Company Profile
TABLE 172: Hologic, Inc.: Company Profile
TABLE 173: Roche Diagnostics: Company Profile
TABLE 174: Danaher Corporation: Company Profile
TABLE 175: Leica Biosystems: Company Profile
TABLE 176: Becton, Dickinson and Company: Company Profile
TABLE 177: Thermo Fisher Scientific: Company Profile
TABLE 178: Illumina, Inc.: Company Profile
TABLE 179: QIAGEN: Company Profile
TABLE 180: Agilent Technologies: Company Profile
TABLE 181: Fujifilm Healthcare: Company Profile
TABLE 182: Canon Medical Systems: Company Profile
TABLE 183: Olympus Corporation: Company Profile
TABLE 184: Boston Scientific Corporation: Company Profile
TABLE 185: Medtronic: Company Profile
TABLE 186: Intuitive Surgical: Company Profile
TABLE 187: Bruker Corporation: Company Profile
TABLE 188: QuidelOrtho Corporation: Company Profile
TABLE 189: Bio-Rad Laboratories: Company Profile
TABLE 190: Revvity, Inc.: Company Profile
TABLE 191: Paige: Company Profile
TABLE 192: PathAI: Company Profile
TABLE 193: Exact Sciences Corporation: Company Profile
TABLE 194: U.S. Cancer Diagnostic Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 195: U.S. Cancer Diagnostic Devices Market: Disruptive Technologies Impact Matrix
TABLE 196: U.S. Cancer Diagnostic Devices Market: Cancer Screening Technology Outlook
TABLE 197: U.S. Cancer Diagnostic Devices Market: Radiology-Pathology-Molecular Integration Outlook
TABLE 198: U.S. Cancer Diagnostic Devices Market: Emerging Business Trends
TABLE 199: U.S. Cancer Diagnostic Devices Market: Business Opportunities for Startups and Existing Players
TABLE 200: U.S. Cancer Diagnostic Devices Market: Investment Prioritization Matrix
TABLE 201: U.S. Cancer Diagnostic Devices Market: Market White-Space Analysis
TABLE 202: U.S. Cancer Diagnostic Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 203: U.S. Cancer Diagnostic Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 204: U.S. Cancer Diagnostic Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 205: U.S. Cancer Diagnostic Devices Market: Strategic Recommendations for Cancer Centers and Diagnostic Networks
TABLE 206: U.S. Cancer Diagnostic Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 207: U.S. Cancer Diagnostic Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 208: U.S. Cancer Diagnostic Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 209: U.S. Cancer Diagnostic Devices Market: U.S. Market Entry and Go-to-Market Strategy
TABLE 210: U.S. Cancer Diagnostic Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 211: U.S. Cancer Diagnostic Devices Market: AI Commercialization Strategy
TABLE 212: U.S. Cancer Diagnostic Devices Market: Partnership, Licensing and Acquisition Opportunity Analysis
TABLE 213: U.S. Cancer Diagnostic Devices Market: Scope Limitation
TABLE 214: U.S. Cancer Diagnostic Devices Market: Market Definition Limitation
TABLE 215: U.S. Cancer Diagnostic Devices Market: Data Use Limitation
TABLE 216: U.S. Cancer Diagnostic Devices Market: Forecasting Limitation
TABLE 217: U.S. Cancer Diagnostic Devices Market: Legal Disclaimer
TABLE 218: U.S. Cancer Diagnostic Devices Market: Third-Party Data Disclaimer
TABLE 219: U.S. Cancer Diagnostic Devices Market: Device, Instrument, Consumable and Service Boundary Disclaimer
TABLE 220: U.S. Cancer Diagnostic Devices Market: Regulatory and Reimbursement Information Disclaimer

List of Figures

FIGURE 1: U.S. Cancer Diagnostic Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem Framework
FIGURE 4: Stakeholder Ecosystem
FIGURE 5: U.S. Cancer Diagnostic Devices Market Executive Snapshot, 2025
FIGURE 6: Market Attractiveness Analysis
FIGURE 7: U.S. Cancer Diagnostic Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 8: U.S. Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 9: U.S. Cancer Diagnostic Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 10: High-Growth Opportunity Map
FIGURE 11: U.S. Cancer Diagnostic Devices Market Dynamics
FIGURE 12: Innovation & Patent Landscape, 2021–2025
FIGURE 13: Cancer Diagnostic Clinical Workflow Economics Framework
FIGURE 14: Hospital Capital Procurement Decision Framework
FIGURE 15: Screening-to-Diagnosis Patient Journey
FIGURE 16: PESTEL Analysis
FIGURE 17: Porter’s Five Forces Analysis
FIGURE 18: Value Chain Analysis
FIGURE 19: Supply Chain Analysis
FIGURE 20: Diagnostic Imaging Installed-Base and Replacement-Cycle Framework
FIGURE 21: Artificial Intelligence Adoption Landscape
FIGURE 22: FDA Regulatory Pathway Framework
FIGURE 23: CMS Reimbursement and Coverage Framework
FIGURE 24: Cancer Screening and Preventive-Care Coverage Landscape
FIGURE 25: Diagnostic Equipment Total Cost of Ownership Framework
FIGURE 26: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 27: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Diagnostic Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Biopsy and Tissue-Acquisition Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Endoscopy and Visualization Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Pathology and Digital Pathology Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Oncology IVD and Molecular Diagnostic Instruments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Diagnostic Modality Segment Market Share Analysis, 2025 & 2035
FIGURE 34: Diagnostic Modality Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Medical Imaging-Based Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Tissue Biopsy-Based Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Endoscopic and Visual Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Digital and Computational Pathology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Molecular and Biomarker-Based Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Cancer Type Segment Market Share Analysis, 2025 & 2035
FIGURE 41: Cancer Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Breast Cancer Diagnostic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Lung Cancer Diagnostic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Colorectal Cancer Diagnostic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Prostate Cancer Diagnostic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Other Cancer Diagnostic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 48: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Cancer Centers and Academic Medical Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Diagnostic Imaging and Breast Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Specialty Clinics and Ambulatory Diagnostic Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Pathology and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: U.S. Cancer Diagnostic Devices Commercial & Procurement Ecosystem
FIGURE 55: IDN and Enterprise Contracting Framework
FIGURE 56: AI Licensing and Software Subscription Model
FIGURE 57: Equipment Replacement and Upgrade Cycle
FIGURE 58: Procurement Decision-Making Framework
FIGURE 59: Regional Market Share Analysis, 2025 & 2035
FIGURE 60: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: West Region U.S. Cancer Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 62: West Region Market Share Analysis by State, 2025
FIGURE 63: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: California Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Washington Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Arizona Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Colorado Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: Oregon Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Utah Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Nevada Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: New Mexico Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Idaho Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Montana Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Wyoming Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 75: Alaska Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 76: Hawaii Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 77: Northeast Region U.S. Cancer Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 78: Northeast Region Market Share Analysis by State, 2025
FIGURE 79: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New York Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Massachusetts Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: New Jersey Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Pennsylvania Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: Connecticut Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: Maine Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Vermont Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: New Hampshire Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 88: Rhode Island Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 89: South Region U.S. Cancer Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 90: South Region Market Share Analysis by State, 2025
FIGURE 91: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Texas Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: Florida Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: Georgia Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: North Carolina Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Tennessee Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: South Carolina Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Alabama Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: Mississippi Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Louisiana Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Arkansas Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Kentucky Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Oklahoma Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: Virginia Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Maryland Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 106: West Virginia Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 107: Delaware Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 108: Midwest Region U.S. Cancer Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 109: Midwest Region Market Share Analysis by State, 2025
FIGURE 110: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Illinois Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Ohio Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: Michigan Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: Minnesota Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: Indiana Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Wisconsin Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 117: Missouri Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 118: Iowa Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 119: Kansas Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 120: Nebraska Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 121: North Dakota Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 122: South Dakota Cancer Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 123: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 124: Company Positioning Matrix
FIGURE 125: Key Player Product Portfolio Benchmarking
FIGURE 126: AI and Digital Capability Benchmarking
FIGURE 127: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 128: U.S. Cancer Diagnostic Devices Innovation Roadmap
FIGURE 129: AI-Assisted Cancer Imaging Adoption Roadmap
FIGURE 130: Digital and Computational Pathology Opportunity Map
FIGURE 131: Robotic and Navigational Biopsy Adoption Roadmap
FIGURE 132: Advanced Breast Imaging Technology Opportunity Map
FIGURE 133: Lung Cancer Screening and Diagnostic Workflow Roadmap
FIGURE 134: Future Market Scenario Analysis, 2026–2035
FIGURE 135: Disruptive Technologies Impact Matrix
FIGURE 136: Radiology-Pathology-Molecular Integration Framework
FIGURE 137: Emerging Business Trends Matrix
FIGURE 138: Investment Prioritization Matrix
FIGURE 139: Market White-Space Opportunity Matrix
FIGURE 140: Technology Adoption Roadmap, 2026–2035
FIGURE 141: Strategic Growth Roadmap for U.S. Cancer Diagnostic Device Companies
FIGURE 142: U.S. Market Entry and Go-to-Market Strategy Framework
FIGURE 143: Product Positioning and Portfolio Expansion Framework
FIGURE 144: AI Commercialization Strategy Framework
FIGURE 145: Partnership, Licensing and Acquisition Opportunity Framework
FIGURE 146: Report Scope and Disclaimer Framework